Dr. Cathy B. Barnes, MD
Family Medicine (Family Medicine Physician)
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
FL license ME54354
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 13 payments worth $1,335 in total to this clinician.
| Merck Sharp & Dohme LLC | $1,335 |
|---|
| Travel and Lodging | $814 |
|---|---|
| Food and Beverage | $521 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jun 23, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $377 |
| Merck Sharp & Dohme LLC Jun 23, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $181 |
| Merck Sharp & Dohme LLC Jun 24, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $181 |
| Merck Sharp & Dohme LLC Jul 21, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL Company’s descriptionProvided as part of a clinical research engagement. | $74.60 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 26 industry-funded studies in 2025, from 10 companies. The companies reported $3,205,744 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT05026866 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company · Active, not recruiting · NCT05738486 - Sherlock Biosciences, Inc. The PROMISE Study
Orasure Technologies Inc. - Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
Eli Lilly and Company · Status unknown · NCT02968303 - A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.